PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer

Colorectal cancer (CRC) is a challenging problem both for the developed and underdeveloped countries. Despite numerous improvements in early diagnosis and treatment, the incidence and mortality is still keeping in a high level. Molecule targeted therapy has drawn much attention as next generation anticancer agents for diagnosis and therapeutic of CRC. Protein Inhibitor of Activated Signal Transducer and Activators of Transcription 3 (PIAS3) as a novel biomarker has been focused to have a role in the development of malignancy, which was expressed at a higher level in most common malignancies compared with corresponding normal tissues. Furthermore, evidences suggest that the expression of PIAS3 can affect the growth of cancer cells by inhibiting the JAK/STAT and PI3-K/Akt signaling pathways or regulating its SUMO (small-ubiquitin like modifiers) ligase activity in some malignancy. Therefore, we hypothesized that PIAS3 may be a potential biomarker target for early cancer detection and therapeutic of human CRC.